Speakers

Arjun Balar, Ashish Kamat, Neal Shore

Arjun Balar, MD

Director, Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center NYU Langone Health
New York, New York





Dr. Balar is an Assistant Professor of Medicine and the Director of the Genitourinary Medical Oncology Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center in New York, New York.

Dr. Balar received his Medical Degree from the University of South Florida-Morsani College of Medicine in Tampa, Florida, as a member of the Alpha-Omega-Alpha Honor Medical Society. He completed his Internal Medicine residency at New York-Presbyterian/Weill Cornell Medical Center in New York, New York, and went on to complete a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York, New York, where his research efforts focused entirely on novel therapies in muscle-invasive and metastatic bladder cancer.

Dr. Balar has focused primarily on cisplatin-ineligible patients with the goal of identifying better tolerated and more effective therapies in advanced and invasive/high-grade urothelial cancer, with a particular focus on novel immunotherapies and combinations.

Back to top

Ashish Kamat, MD, MBBS, FACS

Professor of Urology and Cancer Research Department of Urology
MD Anderson Cancer Center
Houston, Texas


Dr. Kamat is a Professor of Urology and Wayne B. Duddlesten Professor of Cancer Research at MD Anderson Cancer Center in Houston, Texas. He is also the Associate Head of the Cancer Center, Reliance Foundation Hospital in Mumbai, served as the Director of the MD Anderson Urologic Oncology Fellowship Program from 2005-2016 and is a 2008 graduate of the American Urological Association (AUA) Leadership Program.

Dr. Kamat is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ-sparing and minimally invasive techniques. He maintains an active research portfolio in this area with a focus on developing novel therapies, and identifying predictors of response to therapy (eg, intravesical immunotherapy), as a first step toward personalized cancer therapeutics. He has initiated, led, and been active in several large studies, including multinational trials in bladder cancer with findings published in high-impact journals. Dr. Kamat is a Co-Principal Investigator on the MD Anderson GU SPORE (Bladder).

Dr. Kamat is an exceptional educator, and as Program Director, grew the Urologic Oncology Fellowship Program into the premier program in the U.S. He has been nominated twice for the Robert M. Chamberlain Distinguished Mentor Award.

Dr. Kamat has authored numerous editorials, book chapters, and more than 225 publications in peer-reviewed journals, and serves on the editorial board of high-ranked journals. He is listed in "Who’s Who in Medicine’" and "Best Doctors in America" and has won the "Compassionate Doctor Award" from patient groups. He is recognized internationally for his efforts and has been invited as a visiting professor to several universities in the U.S. and elsewhere to deliver invited plenary sessions nationally (American Urological Association [AUA]) and internationally (e.g., European Association of Urology, Japanese Urological Association, Société Internationale d’Urologie, Urological Society of India); to chair related committees (eg, Society of Immunotherapy for Cancer); and as an AUA International Faculty. He is also a member of the AUA Guidelines Panel for Bladder Cancer.

Dr. Kamat is President of the International Bladder Cancer Group and, Co-President of the International Bladder Cancer Network; he Chaired the Bladder Cancer Think Tank and actively participates in various global urologic efforts (eg, setting up cancer centers overseas), serves on the boards of regional and national societies for Urology (South Central Section of the AUA, Texas Urologic Society) and Urologic Oncology (Society of Urologic Oncology Clinical Trials Consortium), and also in patient advocacy groups (MD Anderson Bladder Support Group, Bladder Cancer Advocacy Network, etc.).

Back to top

Neal Shore, MD, FACS

Director and Certified Physician Investigator (CPI)
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina


Dr. Shore is the Medical Director for the Carolina Urologic Research Center and practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.

Dr. Shore has conducted more than 250 clinical trials, focusing mainly on GU Oncology, and serves on the executive boards of the Society of Urologic Oncology, Bladder Cancer Advocacy Network, Society of Urologic Oncology Clinical Trials Consortium, Secretary-Treasurer, and is President, Large Urology Group Practice Association. He is a founder for both CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. Dr. Shore serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee, and currently is a member of the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank. He is on the editorial boards of Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor for Everyday Urology. Dr. Shore has more than 125 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, European Urology, Journal Urology, Urology, BJU International, Prostate Cancer and Prostatic Diseases, and numerous other high impact scientific journals.

A graduate of Duke University and Duke University Medical School, Dr. Shore completed a six-month Clinical Research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York-Presbyterian/Weill Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York, New York. He is a Fellow of the American College of Surgeons.

Back to top